Karikas George A, Schulpis Kleopatra H, Bartzeliotou Anastasia, Regoutas Spyros, Thanopoulou Christina, Papaevangelou Vassiliki, Giannoulia-Karantana Aglaia, Papassotiriou Ioannis, Fytou-Pallikari Athena
Department of Medical Laboratories, Technological and Educational Institute of Athens, Athens, Greece.
Scand J Clin Lab Invest. 2009;69(1):31-5. doi: 10.1080/00365510802248051.
Valproic acid (VPA) treatment and paraoxonase1/arylesterase (PON1/Aryl) activities are related to the production of free radicals. Our aim was to study the PON1/Aryl activities in children on VPA therapy.
Thirty-two children with seizures and 30 healthy child volunteers took part. Ill children underwent the common laboratory tests, as well as total antioxidant status (TAS), total oxidant status (TOS), lipid profile, liver enzymes and PON1/Aryl activities pre- and post-60 days on VPA therapy (30 mg/kg/24 h), whereas the healthy children were tested just once.
None of the studied biochemical parameters differed between volunteers and children with seizures pretreatment. Liver enzymes, lipids and TOS levels (124+/-30 versus 580+/-40 micromol/L; p<0.001) were significantly elevated, whereas the activities of PON1/Aryl (146+/-43 versus 118+/-40 U/mL/min 120+/-42 versus 98+/-38 KU/mL/min; p<0.01) and TAS levels (436+/-42 versus 288+/-39 micromol/L; p<0.001) were decreased in children after treatment. Additionally, strong negative correlations were found between PON1/Aryl activities, liver enzymes, TOS (r = -0.69) and VPA levels (r = -0.57), whereas PON1/Aryl activities correlated positively with TAS, HDL and Apo A-I in all groups.
Serum PON1/Aryl activities were decreased after 60 days on VPA treatment, probably due to liver dysfunction and free radicals production by VPA, without excluding the possibility of a direct action of the drug on the enzymes.
丙戊酸（VPA）治疗与对氧磷酶1/芳基酯酶（PON1/Aryl）活性均与自由基的产生有关。我们的目的是研究接受VPA治疗的儿童的PON1/Aryl活性。
32名癫痫患儿和30名健康儿童志愿者参与了研究。患病儿童在接受VPA治疗（30mg/kg/24小时）前和60天后进行了常规实验室检查，以及总抗氧化状态（TAS）、总氧化状态（TOS）、血脂、肝酶和PON1/Aryl活性检测，而健康儿童仅进行了一次检测。
志愿者与癫痫患儿治疗前的各项生化参数均无差异。肝酶、血脂和TOS水平（124±30对580±40微摩尔/升；p<0.001）显著升高，而治疗后儿童的PON1/Aryl活性（146±43对118±40U/mL/分钟，120±42对98±38KU/mL/分钟；p<0.01）和TAS水平（436±42对288±39微摩尔/升；p<0.001）降低。此外，在所有组中，PON1/Aryl活性与肝酶、TOS（r = -0.69）和VPA水平（r = -0.57）之间存在强负相关，而PON1/Aryl活性与TAS、高密度脂蛋白（HDL）和载脂蛋白A-I呈正相关。
VPA治疗60天后血清PON1/Aryl活性降低，可能是由于肝功能障碍和VPA产生自由基所致，但不排除药物对酶的直接作用。
